FDA Approved: OCREVUS — Supplemental Application (Genentech, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for OCREVUS (ocrelizumab) from Genentech, Inc., authorizing changes to the product's labeling.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Ocrevus (ocrelizumab)

Snippet

SUPPL AP for OCREVUS (OCRELIZUMAB)